Cenisertib benzoate

Overview

Cenisertib (AS-703569) benzoate is an ATP-competitive multi-kinase inhibitor that blocks the activity of Aurora-kinase-A/B, ABL1 , AKT , STAT5 and FLT3 . Cenisertib benzoate induces major growth-inhibitory effects by blocking the activity of several different molecular targets in neoplastic mast cells (MC). Cenisertib benzoate inhibits tumor growth in xenograft models of pancreatic, breast, colon, ovarian, and lung tumors and leukemia.

Application

Products | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > JAK/STAT Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Akt | Products > Signaling Pathways > STAT | Products > Signaling Pathways > FLT3 | Products > Signaling Pathways > Aurora Kinase | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-13072B
• CAS No.: 1145859-64-8
• Molecular Formula: C31H36FN7O3
• Molecular Weight: 573.66
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source